Ocular albinism type 1‑induced melanoma cell migration is mediated through the RAS/RAF/MEK/ERK signaling pathway

Bai,Jun; Xie,Xin; Lei,Yun; An,Gaili; He,Li; Lv,Xiaopeng

doi:10.3892/mmr.2014.2154

Ocular albinism type 1‑induced melanoma cell migration is mediated through the RAS/RAF/MEK/ERK signaling pathway

Authors:
- Jun Bai
- Xin Xie
- Yun Lei
- Gaili An
- Li He
- Xiaopeng Lv
View Affiliations

Affiliations: Department of Medical Oncology, Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of The School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710068, P.R. China, Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Science, Northwest University, Xi'an, Shaanxi 710069, P.R. China, Department of Translational Medicine, Institute of Integrated Medical Information, Xi'an, Shaanxi 710016, P.R. China
Published online on: April 15, 2014 https://doi.org/10.3892/mmr.2014.2154
Pages: 491-495

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma has the highest risk of mortality among all types of skin cancer due to its highly metastatic potential. The ocular albinism type 1 (OA1) protein is a pigment cell‑specific glycoprotein, which shares significant structural and functional features with G protein‑coupled receptors. However, the role of OA1 in melanoma has yet to be elucidated. The present study aimed to investigate whether OA1 is involved in melanoma cell migration. OA1 was found to stimulate cell migration in a dose‑dependent manner in cultured human melanoma cells. Furthermore, knockdown of OA1 using small interfering RNA was observed to significantly inhibit melanoma cell migration. In addition, the mechanism underlying OA1‑induced melanoma cell migration was investigated. Stimulation of the RAS/RAF/mitogen activated protein kinase kinase (MEK)/extracellular signal‑regulated kinase (ERK) pathway using growth factors enhanced OA1 expression and melanoma cell migration, whereas inhibition of this pathway using U0126 was observed to markedly decrease OA1 expression and the number of migrated cells. These findings indicate that OA1 is involved in melanoma cell migration and that OA1‑induced melanoma cell migration is mediated through the RAS/RAF/MEK/ERK signaling pathway. Therefore, OA1 may serve as a novel therapeutic target for melanoma.

View Figures

View References

1	Chakraborty R, Wieland CN and Comfere NI: Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med. 6:49–56. 2013.PubMed/NCBI
2	Tas F: Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012:6476842012.PubMed/NCBI
3	Tsao H, Chin L, Garraway LA and Fisher DE: Melanoma: from mutations to medicine. Gene Dev. 26:1131–1155. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zigler M, Kamiya T, Brantley EC, Villares GJ and Bar-Eli M: PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res. 71:6561–6566. 2011. View Article : Google Scholar : PubMed/NCBI
5	Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, Bonventre JV, Swanson KD and Duffield JS: The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J. 24:4767–4781. 2010. View Article : Google Scholar
6	Das SK, Bhutia SK, Sokhi UK, Azab B, Su ZZ, Boukerche H, Anwar T, Moen EL, Chatterjee D, Pellecchia M, Sarkar D and Fisher PB: Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. Cancer Res. 72:6217–6226. 2012. View Article : Google Scholar : PubMed/NCBI
7	Fernandez LP, Milne RL, Pita G, Floristan U, Sendagorta E, Feito M, Avilés JA, Martin-Gonzalez M, Lázaro P, Benítez J and Ribas G: Pigmentation-related genes and their implication in malignant melanoma susceptibility. Exp Dermatol. 18:634–642. 2009. View Article : Google Scholar : PubMed/NCBI
8	Schiaffino MV: Signaling pathways in melanosome biogenesis and pathology. Int J Biochem Cell Biol. 42:1094–1104. 2010. View Article : Google Scholar : PubMed/NCBI
9	Giordano F, Simoes S and Raposo G: The ocular albinism type 1 (OA1) GPCR is ubiquitinated and its traffic requires endosomal sorting complex responsible for transport (ESCRT) function. Proc Natl Acad Sci USA. 108:11906–11911. 2011. View Article : Google Scholar : PubMed/NCBI
10	Palmisano I, Bagnato P, Palmigiano A, Innamorati G, Rotondo G, Altimare D, Venturi C, Sviderskaya EV, Piccirillo R, Coppola M, et al: The ocular albinism type 1 protein, an intracellular G protein-coupled receptor, regulates melanosome transport in pigment cells. Hum Mol Genet. 17:3487–3501. 2008. View Article : Google Scholar : PubMed/NCBI
11	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
12	Hilger RA, Scheulen ME and Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 25:511–518. 2003. View Article : Google Scholar : PubMed/NCBI
13	Marshall C: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:179–185. 1995. View Article : Google Scholar
14	Bogenrieder T and Herlyn M: The molecular pathology of cutaneous melanoma. Cancer Biomark. 9:267–286. 2011.
15	Forsea A, Del Marmol V, de Vries E, Bailey EE and Geller AC: Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol. 167:1124–1130. 2012. View Article : Google Scholar : PubMed/NCBI
16	Bhatia S, Tykodi SS and Thompson JA: Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 23:488–496. 2009.
17	Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
18	McKenzie JA, Liu T, Goodson AG and Grossman D: Survivin enhances motility of melanoma cells by supporting Akt activation and alpha5 integrin upregulation. Cancer Res. 70:7927–7937. 2010. View Article : Google Scholar : PubMed/NCBI
19	Marino N, Marshall JC and Steeg PS: Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1. Naunyn Schmiedebergs Arch Pharmacol. 384:351–362. 2011. View Article : Google Scholar : PubMed/NCBI
20	Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
21	Agell N, Bachs O, Rocamora N and Villalonga P: Modulation of the Ras/Raf/MEK/ERK pathway by Ca²⁺, and Calmodulin. Cell Signal. 14:649–654. 2002. View Article : Google Scholar : PubMed/NCBI
22	Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA and McCubrey JA: Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 17:1263–1293. 2003. View Article : Google Scholar
23	Panka DJ, Wang W, Atkins MB and Mier JW: The Raf inhibitor BAY 43–9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 66:1611–1619. 2006.
24	Sebolt-Leopold JS: MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des. 10:1907–1914. 2004. View Article : Google Scholar : PubMed/NCBI
25	Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M and Tuveson DA: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63:5198–5202. 2003.PubMed/NCBI